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Resolution of inflammation is defective after spinal cord injury (SCI), which impairs tissue integrity and remodeling and leads to
functional deficits. Effective pharmacological treatments for SCI are not currently available. Maresin 1 (MaR1) is a highly conserved
specialized proresolvingmediator (SPM) hosting potent anti-inflammatory and proresolving properties with potent tissue regenerative
actions. Here, we provide evidence that the inappropriate biosynthesis of SPM in the lesioned spinal cord hampers the resolution of
inflammation and leads to deleterious consequences on neurological outcome in adult female mice. We report that, after spinal cord
contusion injury in adult female mice, the biosynthesis of SPM is not induced in the lesion site up to 2 weeks after injury. Exogenous
administration ofMaR1, a highly conserved SPM, propagated inflammatory resolution after SCI, as revealed by accelerated clearance of
neutrophils and a reduction in macrophage accumulation at the lesion site. In the search of mechanisms underlying the proresolving
actions of MaR1 in SCI, we found that this SPM facilitated several hallmarks of resolution of inflammation, including reduction of
proinflammatory cytokines (CXCL1, CXCL2, CCL3, CCL4, IL6, and CSF3), silencing of major inflammatory intracellular signaling cas-
cades (STAT1, STAT3, STAT5, p38, andERK1/2), redirection ofmacrophage activation toward aprorepair phenotype, and increase of the
phagocytic engulfment of neutrophils by macrophages. Interestingly, MaR1 administration improved locomotor recovery significantly
andmitigated secondary injury progression in a clinical relevantmodel of SCI. These findings suggest that proresolution, immunoresol-
vent therapies constitute a novel approach to improving neurological recovery after acute SCI.
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Significance Statement
Inflammation is a protective response to injury or infection. To result in tissue homeostasis, inflammation has to resolve over
time. Incomplete or delayed resolution leads to detrimental effects, including propagated tissue damage and impaired wound
healing, as occurs after spinal cord injury (SCI).We report that inflammation after SCI is dysregulated inpart due to inappropriate
synthesis of proresolving lipidmediators.Wedemonstrate that the administrationof the resolution agonist referred to asmaresin
1 (MaR1) after SCI actively propagates resolution processes at the lesion site and improves neurological outcome. MaR1 is
identified as an interventional candidate to attenuate dysregulated lesional inflammation and to restore functional recovery
after SCI.
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Introduction
Spinal cord injury (SCI) causes an immune response (David et
al., 2012a; Gomez-Nicola and Perry, 2015; Steinman, 2015) com-
posed of activated resident glial cells (microglia and astrocytes)
and blood-derived leukocytes (neutrophils,monocytes, and lym-
phocytes) that enter the damaged spinal cord (Hawthorne and
Popovich, 2011; Pru¨ss et al., 2011; David et al., 2012a). These
immune cells are required for effective clearance of damaged cell
and myelin debris and for the release of bioactive molecules that
lead to tissue healing and repair (Popovich and Longbrake, 2008;
David et al., 2012a). However, they also secrete several factors
that mediate cytotoxicity to neurons, glia, axons, and myelin
(Popovich and Longbrake, 2008; David et al., 2012a). Therefore,
the inflammatory response exerts both helpful and detrimental
actions after SCI, so its final outcome on this pathology depends
on the balance between mechanisms that regulate different as-
pects of the inflammatory response.
A self-limited inflammatory response is a prerequisite for a
return to homeostasis (catabasis) and requires effective resolu-
tion of inflammation (Buckley et al., 2014; Serhan, 2014; Serhan
et al., 2015). In contrast, insufficient or inadequate resolution
leads to chronic inflammation that causes greater tissue damage,
impaired tissue remodeling, and inappropriate tissue healing,
such as pronounced deposition of extracellular matrix (Buckley
et al., 2014; Serhan, 2014; Serhan et al., 2015). This is also the case
after SCI, when inflammation fails to resolve properly, leading to
disproportionate harmful bystander side effects (Hawthorne and
Popovich, 2011; Pru¨ss et al., 2011; David et al., 2012a). The dam-
aging consequences of nonresolving inflammation are pronounced
in the lesioned spinal cord due to the limited capacity of repair, such
as axon regeneration and replacement of damagedneurons andmy-
elin, leading to irreversible functional disabilities (Fawcett et al.,
2012; Lu et al., 2014; Stenudd et al., 2015).
Resolution of inflammation is an active process regulated in
part by a superfamily of lipid mediators derived from polyunsat-
urated fatty acids (PUFAs) (Schwab et al., 2007; David et al.,
2012c; Serhan, 2014). This superfamily of specialized proresolv-
ing mediators (SPMs) include: lipoxins, resolvins [resolvin D
(RvD) and resolvin E (RvE)], protectins, and maresins (Buckley
et al., 2014; Serhan, 2014; Serhan et al., 2015). SPMs actively turn
off the inflammatory response by acting on distinct G-protein-
coupled receptors expressed on immune cells that activate dual
anti-inflammatory and proresolution programs (Buckley et
al., 2014; Serhan, 2014; Serhan et al., 2015). Among the anti-
inflammatory actions of SPMs include the induction in the
expression of anti-inflammatory cytokines or inflammatory
scavenging molecules such as IL-10, IL-1 decoy receptors, and
IL-1 receptor antagonists (Buckley et al., 2014; Serhan, 2014).
Conversely, SPMs activate specific mechanisms that trigger the
resolution of inflammation, including the following: (1) down-
regulation of proinflammatory cytokines, (2) abrogation of in-
tracellular pathways that lead to inflammation, (3) clearance of
inflammatory cell detritus (such as apoptotic neutrophils) by
macrophages, and (4) normalization of immune cells counts to
basal levels also referred to as catabasis (Buckley et al., 2014;
Serhan, 2014; Serhan et al., 2015). The importance of SPMs in the
resolution of inflammation is evident in many chronic patholog-
ical conditions in which their production is insufficient, delayed,
or even absent, and exogenous administration of SPMs reduces
inflammation and mediates tissue protection (Schwab et al.,
2007; Buckley et al., 2014). However, it is currently not known
whether sustained inflammation in SCI is due to inadequate pro-
duction of SPMs.
Here, we show that SPM biosynthesis is impaired after SCI
and that systemic administration ofMaresin 1 (MaR1) (Serhan et
al., 2009), a docosahexaenoic acid (DHA)-derived SPM, is able to
enhance resolution of inflammation, resulting in improved func-
tional and histopathological outcomes. These results provide
strong evidence about the beneficial effects of exogenous admin-
istration of MaR1 in a preclinical model of SCI and suggest that
administration of SPMs could be a novel therapeutic approach to
treat acute SCI in humans, for which there is currently no effec-
tive treatment.
Materials andMethods
SCI and MaR1 treatment. All surgical procedures were approved by the
Universitat Auto`noma de Barcelona Animal Care Committee and fol-
lowed the guidelines of the European Commission on Animal Care. The
methods for each procedure were performed in accordance with the
approved guidelines. A total of 142 adult (8–10 weeks old) female
C57BL/6 mice (Charles River Laboratories) were anesthetized with ket-
amine:xylazine (90:10 mg/kg). After performing a laminectomy at the
11th thoracic vertebrae, the exposed spinal cord was contused using the
InfiniteHorizon Impactor device (Precision Scientific Instrumentation).
Injuries were made using a force of 60 kilodynes and tissue displacement
ranging between 500 and 700 m, as described previously (Coll-Miro´ et
al., 2016).
One hour after SCI, 1 g of MaR1 (7S,14S-dihydroxy-4Z, 8E, 10E,
12Z, 16Z, 19Z-DHA; Cayman Chemical) or vehicle was injected intrave-
nously and then repeated daily thereafter until day 7. The injected solu-
tion was always prepared from the MaR1 stock solution the day of the
administration. This consisted of 1 g of MaR1 (10 l of the stock solu-
tion) diluted in 100 l of saline at 37°C. The solution was prepared in
individual Eppendorf tubes (one permouse) and injected within the first
15 min after its preparation. Vehicle solution consisted of 10 l of 100%
alcohol in 100 l of saline at 37°C. Although we delivered this solution
intravenously, we now have data indicating that intraperitoneal admin-
istration is also effective. TheMaR1 dosage was chosen accordingly to be
above the levels of approved MaR1 bioactivity in experimental disease
models (Serhan et al., 2015) and above the SPM dosages sufficient to
exert bioactivity in the CNS with intact and closed blood–brain barrier
(Marcheselli et al., 2003; Svensson et al., 2007).
Flow cytometry. To study the dynamics of immune cells in SCI, im-
mune cells from the laminectomized and injured spinal cord were ana-
lyzed by flow cytometry at 1, 3, 7, 14, 21, and 28 d postinjury (dpi) as
described previously (Santos-Nogueira et al., 2015; Coll-Miro´ et al.,
2016; Francos-Quijorna et al., 2016). Similarly, spinal cords from mice
treated with MaR1 or saline were also harvested at day 1, 3, and 7 after
lesion. Briefly, spinal cords were cut in small pieces and passed through a
cell strainer of 70 m (BD Falcon) and the cell suspension was centri-
fuged twice at 300 g for 10 min at 4°C. After cell counts, samples were
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divided and cells alone and isotype-matched control samples were gen-
erated to control for nonspecific binding of antibodies and for autofluo-
rescence. The following antibodies from eBioscience were used at a 1:250
concentration: CD45-PerCP, CD11b-PE-Cy7, Ly6C-FITC, Ly6G-PE,
Gr1-FITC, F4/80-APC or PE, CD3-FITC, CD4-APC, CD8-APC, CD19-
PE, CD206-FITC, and CD16/32-PE. After 30 min of incubation with
combinations of antibodies at 4°C, cells were fixed in 1% paraformalde-
hyde. For intracellular staining, cells were permeabilized with Permeabi-
lization Wash Buffer (BioLegend), incubated with unconjugated rabbit
antibodies against iNOS (1:200; Abcam), and goat antibodies against
Arg1 (1:200; Santa Cruz Biotechnology) for 30 min, followed by staining
with Alexa Fluor 488- or Alexa Fluor 647-conjugated donkey secondary
antibodies against rabbit or goat (1:500; Invitrogen) for 30 min. Finally,
samples were washed and fixed in 1%paraformaldehyde. To perform the
analysis, cells were first gated for CD45 to ensure that only infiltrating
leukocytes and resident microglia were selected. Then, a combination of
markers were used to identify the following: for microglia, CD45 low,
CD11b, and F4/80; for macrophages, CD45high, CD11b, and F4/
80; for neutrophils, CD45high, CD11b, F4/80, andGr1high; for CD4
T cells, CD45, CD11b, CD3, and CD4; for CD8 T cells, CD45,
CD11b, CD3, and CD8; and for B cells, CD45, CD11b, CD3,
and CD19. To study the phenotype of microglia and macrophages,
these cells were further differentiated based on Ly6C, CD16/32, iNOS,
CD206, andArg1 expression (Coll-Miro´ et al., 2016; Francos-Quijorna et
al., 2016). Analysis of inflammatory cell kinetics at the lesion site was con-
ducted applying objective andquantifiablemeasures of resolutiondynamics
as described previously (Pru¨ss et al., 2011). Cells were analyzed using FlowJo
software on a FACSCanto flow cytometer (BD Biosciences).
Lipidmediator lipidomics. A 5mm segment of uninjured and contused
spinal cord centered on the lesion tissue was harvested at 1, 3, 7, and 14
dpi for LC-MS/MS. Briefly, for endogenous lipid autacoid analysis, fro-
zen spinal cords were homogenized with a hand-held tissue grinder in
66%methanol (4°C). Homogenized tissue samples were combined with
2 volumes of methanol (4°C). Themethanol contained deuterated inter-
nal standards, PGE2-d4, lipoxin A4 (LXA4)-d5, leukotriene B4 (LTB4-
d4), 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE-d8], arachidonic
acid (AA)-d8, and DHA-d54 at 400 pg/each to calculate recovery of
different classes of oxygenated fatty acids and PUFAs. Lipid autacoids
were extracted by solid phase using Accubond ODS-C18 cartridges
(Agilent Technologies). Eicosanoids, docosanoids, and PUFAs were
identified and quantified by LC/MS/MS-based lipidomics (Hassan and
Gronert, 2009; Pru¨ss et al., 2013). In brief, extracted samples were ana-
lyzed by a triple quadruple linear ion trap LC/MS/MS system (MDS
SCIEX 3200 QTRAP) equipped with a LUNA C18-2 mini-bore column
using a mobile phase (methanol:water:acetate, 65:35:0.02, v:v:v) with a
0.50ml/flow rate.MS/MS analyses were performed in negative ionmode
and hydroxy fatty acids were quantified bymultiple reactionmonitoring
using established transitions. Calibration curves (1–1000 pg) and specific
LC retention times for each compound were established with synthetic
standards (Cayman Chemical).
Cytokine protein expression. Mice treated with saline or MaR1 were
perfused with sterile saline and a 5 mm length of spinal cord centered on
the lesion was collected at 12 and 24 h after contusion injury and snap
frozen. Spinal cords were homogenized and protein concentration was
determined using the DC Protein Assay (Bio-Rad). Samples were con-
centrated to 4g/l usingMicroCon centrifugation filters (Millipore) to
ensure equal amounts of protein. Low concentrations of cytokines in the
sample result in binding to the filters, whereas high concentrations of
protein sustain fewer losses. The protein levels of 32 cytokines and
chemokines were then analyzed using the Milliplex MAP Mouse Cyto-
kine/Chemokine magnetic bead panel (Millipore) on a Luminex (Milli-
pore) as per themanufacturer’s protocol (Francos-Quijorna et al., 2016).
Western blotting. Samples used for the Luminex assay were also used
forWestern blotting. Protein samples (30g) were separated by electro-
phoresis on a 10–15% polyacrylamide gel and transferred onto PVDF
membranes (Millipore). The membranes were incubated overnight at
4°C with rabbit antibodies against phospho NF-B p65 (1:1000; Cell
Signaling Technology), against the phosphorylated form of STAT1 (1:
500; Cell Signaling Technology), STAT3 (1:500; Cell Signaling Technol-
ogy), STAT5 (1:500; Cell Signaling Technology) and STAT6 (1:500; Cell
Signaling Technology), JNK (1:500; Santa Cruz Biotechnology), ERK1/2
(1:1000; Cell Signaling Technology), p38 (1:1000; Cell Signaling Tech-
nology), and AKT (1:1000; Cell Signaling Technology). Bands were
detected using chemiluminescence (Immobilon Western Chemilu-
minescence HRP reagent; Millipore) and data were quantified by den-
sitometry using Workflow version 3 software in a Chemidoc apparatus
(Millipore). -Actin (1:10.000; Sigma-Aldrich) was used to ensure equal
loading of samples.
Functional assessment. Locomotor recovery was evaluated at 1, 3, 5, 7,
10, 14, 21, and 28 d postinjury (dpi) in an open-field test using the
nine-point Basso Mouse Scale (BMS) (Basso et al., 2006), which was
developed specifically for locomotor testing after contusion injuries in
mice. The BMS analysis of hindlimb movements and coordination was
performed by two independent assessors blinded to the treatment groups
(MaR1 vs saline) and the consensus score taken. In addition, at the end of
the follow-up (28 dpi), a computerized assessment of locomotion was
also performed using the DigiGait Imaging System (Mouse Specifics).
This system consists of a motorized transparent treadmill belt and a
high-speed digital video camera that captures images of the paws from
the underside of the walking animals. DigiGait software generates “digi-
tal pawprints” and dynamic gait signals, representing the temporal re-
cord of paw placement relative to the treadmill belt. This locomotor test
allows for an easy and objective analysis of both static and dynamic
locomotor parameters. Moreover, the highest locomotion speed that
each mouse was able to locomote for at least 5 s was also recorded on the
DigiGait treadmill belt. Functional tests were done blinded to the exper-
imental groups.
Histology. At 28 dpi, mice were perfused with 4%paraformaldehyde in
0.1 M-phosphate buffer (PB). A 5 mm length of spinal cord containing
the lesion site was removed, cryoprotected with 30% sucrose in 0.1 M PB
at 4°C, and 10 series of 10-m-thick sections were picked up on glass
slides. Adjacent sections on the same slide were therefore 100 m apart.
For quantification of myelin area content in the spinal cord analyses,
sections were stained with Luxol Fast Blue (LFB; Sigma). For neuronal
and axonal assessment, sections were incubated overnight at 4°C with
biotinylated antibodies against NeuN (1:200;Millipore) andNF (1:1000;
Millipore), respectively. Double immunostaining for NF and myelin-
binding protein (MBP, 1:100; Abcam) was done to assess the sparing of
myelinated axons. Sections were incubated for 1 h at room temperature
with the streptavidin/Alexa Fluor 594-conjugated or donkey anti-rabbit
Alexa Fluor 594-conjugated antibodies (1:500; Invitrogen) and then cov-
erslipped in Mowiol containing DAPI to label nuclei.
The epicenter of the injection or contusion injury impact was deter-
mined for eachmouse spinal cord by localizing the tissue sectionwith the
greatest damage using an LFB-stained section. Myelin content after SCI
was calculated by delineating the area of LFB-stained tissue. Neuronal
survival was assessed by counting the number of NeuN cells in the
ventral horns at the injury epicenter and at rostral and caudal areas.
Axonal sparing was calculated by counting the number of axons in the
dorsal column at the injury epicenter, the region of most pronounced
damage. The same sections were used to examine axonal demyelination
in the dorsal column through counting the fibers double stained for NF
and MBP at the lesion epicenter. All quantifications were performed
blinded to the experimental groups with the help of the ImageJ image
analysis software.
Statistical analyses. Data are shown as mean SEM. The Kolmogoro-
v–Smirnov test was used to test normality. Dependent on data being
normally or non-normally distributed, we chose parametric or nonpara-
metric tests. Dynamics of immune cell recruitment and lipidomic profile
after SCIwere analyzedwith one-wayANOVAwith post hocBonferroni’s
test. Functional follow-up for BMS score and subscore, as well as histo-
logical analysis of myelin and neuronal sparing, were analyzed using
two-way repeated-measures ANOVA with post hoc Bonferroni’s post hoc
test for multiple comparisons. Two-tailed Student’s or the nonparamet-
ric Mann–Whitney’s test was used for single comparisons between two
groups and one-way ANOVA followed by Dunnett’s multiple post hoc
test for comparisons of more than two groups. Maximal speed on a
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treadmill was analyzed using theMantel–Cox test. Differences were con-
sidered significant at p 0.05.
Results
Inflammatory cell clearance is impaired after SCI
We first evaluated, using flow cytometry, the dynamics of the
main inflammatory cell types in the contused spinal cord of
C57BL/6mouse and assessed different parameters to characterize
the inflammatory resolution and to determine the persistence of
the different immune cell subpopulations at the lesion site after
spinal cord contusion in mice. We detected that the accumula-
tion of neutrophils, macrophages, and microglia cell reached
maximal cell numbers in the contused spinal cord at 1, 3, and
7 dpi, respectively (Fig. 1A–C). Subsequently, their numbers
dropped progressively up to 7–14 dpi, remaining at high and
steady levels up to 28 dpi (Fig. 1A–C). The resolution index (Ri,
the window between the time point of maximum cell numbers to
a reduction by 50%) of neutrophils andmacrophages was 2.5 and
9.5 d, respectively, reflecting the slower clearance ofmacrophages
in SCI compared with neutrophils. Microglia Ri could not be
calculated because of the rapid decline in their cell counts from 7
to 14 dpi; however, it was7. We then quantified the resolution
plateau (Rp, the percentage of persistent cellular component rel-
ative to maximum cell numbers) to provide quantitative mea-
surements of the inflammatory resolution after SCI (Pru¨ss et al.,
2011). Rp revealed that the clearance of all three myeloid cell
subsets after SCI was incomplete, with35% remaining neutro-
phils, macrophages, and microglial cells at 28 dpi (Fig. 1A–C).
We also studied the recruitment of lymphocytes in the con-
tused spinal cord. We observed infiltration of B cells and T cells,
both CD4 and CD8 lymphocytes, during the first few days
after contusion injury, but at much lower numbers compared
withmonocytes (Fig. 1D–F). Rp of the different lymphocyte sub-
sets was 50% at day 28, indicating the persistent presence of
lymphocytes in SCI exposed to CNS antigens throughout. These
results provide clear evidence that immune cells are not elimi-
nated efficiently from the contused spinal cord and highlight that
the resolution capacity of the injured spinal cord is impaired after
SCI.
Defective lipid mediator class switch as a classical hallmark of
impaired resolution in acute SCI lesions
We investigated whether the impaired clearance of inflammatory
cells is mirrored by failed induction of synthesis of SPMs, which
have been identified as being crucial for efficient resolution (Ser-
han, 2014). Lipidomic analysis of spinal cord revealed delayed
synthesis of SPM after contusion injury. The levels of 12-HETE
and 15-HETE, which are pathway markers of the synthesis of the
AA-derived SPMs known as LXA4, did not increase until 14 dpi
(Fig. 2; one-way ANOVA, Bonferroni’s post hoc test, F(4,15) 	
5214 for 12-HETE; F(4,15)	 4074 for 15-HETE p 0.05) Levels
of 5-HETE, however, did not change after injury (Fig. 2). Simi-
larly, the synthesis of SPMs derived from DHA was also delayed
in SCI because the levels of 17-HDHA, a pathway marker for the
formation of RvD and protectin D1 (PD1), and 14-HDHA, the
pathway marker for the biosynthesis of MaR1, were not induced
until day 14 (one-way ANOVA, Bonferroni’s post hoc test, F(4,15)	
2475 for 17-HDHA; F(4,15) 	 4174 for 14-HDHA; p  0.05).
Moreover, SPM derived from eicosopentaenoic acid (EPA) were
also impaired after SCI because 18-HEPE, the pathway marker
for the formation of the RvE series, was undetected in the injured
spinal cord for the time period analyzed (14 d). Therefore, the
CNS lesion milieu is characterized by a defective and delayed
induction of SPMs involving those derived from the AA (-6),
DHA, and EPA (-3) pathways, which are required for orches-
trating efficient resolution of inflammation. This inability to gen-
erate a resolution conducive milieu is contrasted by a full-blown
early PGE2 response as a hallmark of proinflammatory activity
(one-way ANOVA, Bonferroni’s post hoc test, F(4,15)	 10,14; p
0.05; Fig. 2). These data indicate that the class switch from pro-
inflammatory to proresolution lipid mediators derived from AA,
DHA, and EPA does not occur properly in the injured spinal
cord.
MaR1 regulates resolution of inflammation in the injured
spinal cord
To assess whether the deficit in the resolution of inflammation
after SCI is linked to impaired synthesis of SPM, we investigated
Figure 1. Temporal dynamics of changes in leukocyte numbers at the lesion site after SCI inmice. A–F, Graphs showing neutrophil (A), macrophage (B), microglial (C), CD4 T-cell (D), CD8 T-cell
(E), and B-cell (F ) kinetics in the contused spinal cord for the first 4 weeks. Note that the counts for the different immune cell populations remained elevated throughout this period. Dashed lines
indicate the resolution plateau (Rp). *p 0.05 versus laminectomy (L). One-way ANOVA with Tukey’s post hoc correction (n	 8 per point). Error bars indicate SEM.
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whether systemic administration of theDHA-derived SPMcalled
MaR1 enhanced immune cell clearance from the contused spinal
cord.We first assessed the effects ofMaR1 on neutrophil dynam-
ics (two-way ANOVA, Bonferroni’s post hoc test; effect of day
F(3,40)	 63.68, p 0.0001; effect of treatment F(1,40)	 3.424, p	
0.0317). Daily intravenous administration of MaR1 for 7 d start-
ing 1 h after SCI did not impede the infiltration of neutrophils
into the contused spinal cord because their counts at 1 dpi, when
neutrophil accumulation peaks after SCI, were unaltered by
MaR1 treatment (Fig. 3). However, MaR1 accelerated the clear-
ance of neutrophils from the contused spinal cord based on sev-
eral resolutions parameters (Ri and T50), and reduced50% the
neutrophil counts in the injured spinal cord at day 7 (Fig. 3). We
next studied whether MaR1 interfered with the recruitment of
macrophages after SCI (two-way ANOVA, Bonferroni’s post hoc
test; effect of day F(3,40)	 57.39, p 0.0001; effect of treatment
F(1,40)	 3.932, p	 00543). The entrance of bloodborne macro-
phages into the contused spinal cord was not different at day 1
after MaR1 treatment (Fig. 4A–C), but tended to be reduced at 3
dpi, although not significantly. However, macrophage accumu-
lation in the lesioned spinal cord was reduced significantly after
MaR1 treatment at 7 dpi (Fig. 4A–C). MaR1 treatment did not
attenuate microglial numbers in the contused spinal cord during
the first week after contusion injury, although it tended to be
reduced at 7 dpi upon administration of this SPM (Fig. 4D).
These results provide clear evidence that
systemic delivery of MaR1 enhances the
elimination of peripheral myeloid cells
(neutrophils and macrophages) from the
injured spinal cord, suggesting an impor-
tant role for MaR1 in promoting resolu-
tion of inflammation after SCI.
MaR1 silences cytokine expression
in SCI
In an attempt to assess the mechanisms
underlying the resolving actions of MaR1
in SCI, we assessed changes in expression
of cytokines at the protein level in the con-
tused spinal cord using a Luminex assay.
These experiments revealed that MaR1
treatment reduced the levels of CXCL1,
CXCL2, CCL3, CCL4, IL-6, and CSF3 sig-
nificantly (one-way ANOVA, Dunnet’s
post hoc test, F(3,14) 	 7.78, p  0.05; Fig.
5A; Table 1). In addition, the expression
of IL-3, IL-13, and CXCL5, which were
found at low levels in contused spinal
cords of mice treated with vehicle, were
undetectable in those treated with MaR1
(Table 1). IL-4 protein levels were unde-
tected in the injured spinal cord of both
groups. Note that MaR1 did not reduce the
protein levels of the anti-inflammatory cy-
tokine IL-10 after SCI (Fig. 5A), suggesting
that MaR1 attenuates proinflammatory cy-
tokines preferentially.
Because cytokines are regulated by
multiple signal transduction pathways, we
then investigated which of the main in-
flammatory signaling mechanisms were
attenuated by MaR1 after SCI. Western
blot analysis of spinal cord tissue taken
24 h after SCI revealed that levels of pP65 and pAkt were upregu-
lated after contusion injury, but these levels were not affected by
MaR1 treatment (one-way ANOVA, Dunnet’s post hoc test,
F(2,7) 	 2.44, p 	 0.562; Fig. 5B,C). In contrast, the STAT and
MAPK pathways, two of the main inflammatory signaling
mechanisms, showed differences after SCI. Specifically, STAT1,
STAT3, and STAT5, as well as p38 and ERK1/2, were increased
significantly at 24 h after injury in saline-treated mice and all of
them were attenuated uponMaR1 treatment (one-way ANOVA,
Dunnet’s post hoc test, F(2,7), p  0.05; Fig. 5B,C). STAT6 and
JKN, which were not activated significantly after SCI, remained
unaltered after MaR1 administration. These data provide clear ev-
idence that MaR1 silences cytokine expression and turns off the
activation of somemembers of the STAT andMAPKproinflamma-
tory signaling pathways, but does not limit NF-B and PI3K/Akt
signaling after SCI.
Actions of MaR1 onmicroglia andmacrophage after SCI
Macrophages are a heterogeneous population of cells that exert
divergent effects on damaged tissue depending on their pheno-
type. Ly6Chigh macrophages are proinflammatory and exhibit
phagocytic, proteolytic functions and mediate cytotoxicity. In
contrast, Ly6Clow (also known as LyC6neg)macrophages are anti-
inflammatory and promote wound healing and repair (Arnold et
al., 2007; Nahrendorf et al., 2007). Because cytokines play a key
Figure 2. Impaired and delayed synthesis of proresolving lipid mediators after SCI. Resolution metabolome profiles after SCI
were analyzed using LC-MS/MS of whole spinal cord lysates. Proinflammatory eicosanoid profiles indicated by PGE2 levels follow
closely the formation of inflammation, with an early increase at day 1, increasing to peak at day 7, followed by a drop until day 14.
This time point marks a switch in the lipid mediator biosynthesis profile demarcated by starting increase of the proresolution
pathways. Both MaR1 and RvD synthesis commences not before 2 weeks after SCI as indicated by a 10- to 13-fold increase of the
pathway markers such as 14-HDHA (MaR1) or 17-HDHA (RvD and NP1). This is further matched by the weak and late induction of
5-HETE, 12-HETE, and 15-HETE,which are indicative of the biosynthesis of the SPMLA4. Note that at 14 dpi, proresolving pathways
are increased significantly in the injured spinal cord,with the exceptionof RvE, the levels ofwhichwerebelow the limit of detection
(BLD). Conversely, the levels of the proinflammatory eicosanoid PGE2 were not increased at this time point. *p 0.05 versus
uninjured spinal cords (0 d). One-way ANOVA with Bonferroni’s post hoc correction (n	 4 per point). Error bars indicate SEM.
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role in regulating macrophage phenotype (David and Kroner,
2011; Kroner et al., 2014), we investigated whether MaR1 mod-
ulated the proportion of Ly6Chigh and Ly6Clow macrophages at
7 d after SCI, the time point when MaR1 treatment reduced the
number of these cells. We found that MaR1 had a significant
impact onmacrophage phenotype based on Ly6C expression be-
cause this SPM reduced (50%) the amount of proinflammatory
macrophages (Ly6Chigh) markedly, but not the anti-inflammatory
macrophages (Ly6Clow) (Fig. 6A,B). Indeed, the ratio of LyC6low/
LyC6high in saline-treated SCImicewas 1.570.39. In contrast, this
ratiowas increased to3.730.26byMaR1(t test, t	4.201; df	10;
p 	 0.0036), highlighting that there were 4-fold greater anti-
inflammatory than proinflammatory macrophages in the spinal
cord of mice treated withMaR1 (Fig. 6A,B).
This SPM also reduced expression of the proinflammatory,
cytotoxic enzyme iNOS significantly (Fig. 6C,E) in macrophages
Figure 3. MaR1 propagates the resolution of neutrophil inflammation. A, B, Representative density plots of FACS analysis showing neutrophils at 1, 3, and 7 d after the injury in the spinal cord
of saline- (A) and MaR1 (B)-treated mice. C, Graph showing neutrophil recruitment and resolution indices. Note that MaR1 treatment (red line) does not interfere with the proinflammatory cell
infiltration, but induces amore rapid decline of neutrophils. Inset shows some inflammatory kineticsmeasurement, which include:max	maximal cell counts;3 and7	 cell counts at 3 and
7 dpi; Tmax, time after SCI until reachingmax cell numbers, T50, time after SCI until reduction of cell numbers by 50%; and Ri. *p 0.05 versus saline. Two-way ANOVAwith Bonferroni’s post hoc test
was used to analyze significant differences in the dynamics of neutrophil counts after SCI; t test was used to assess the different inflammatory kinetic indices (n	 6 per time point and group). Error
bars indicate SEM.
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(t test, t	 4.779; df	 10; p	 0.0007). Moreover, MaR1 induced
a 2-fold increase of Arg-1 expression in macrophages, which
was barely detectable in vehicle controls, although it did not reach
statistical significance (t test, t	 1.288; df	 10; p	 0.2266; Fig.
6C,E). Together, these data indicate that MaR1 converts the phe-
notype of macrophages in the injured spinal cord toward a more
prorepair and anti-inflammatory state.
In contrast to macrophages, most microglial cells were Ly6Clow
in SCI (85%) and MaR1 did not reduce the percentage of
Ly6Chigh microglia (9.6  0.8% and 10.6  1.1% in saline- and
MaR1-treated mice, respectively). MaR1 treatment tended to re-
duce the expression of iNOS (Fig. 6D,F), although not to a sta-
tistically significant level. These results, therefore, suggest that the
immunomodulatory effects of MaR1 after SCI are mostly related
to macrophages but not microglia, at least up to 7 dpi.
Because phagocytosis of neutrophils by macrophages is a cru-
cial step for the resolution of inflammation (Schwab et al., 2007;
Serhan, 2014; Serhan et al., 2015), we determined whether MaR1
increased the ability of macrophages to phagocytose neutrophils
(efferocytosis). We found that the amount of the selective neutro-
philmarker Ly6G inside themacrophages (CD45high, CD11b, F4/
80) was increased 2-fold in the spinal cords of mice treated
Figure 4. MaR1 propagates late macrophage clearance from the lesion site. A, B, Representative FACS analysis dot plots showing the dynamics of macrophages accumulation in the spinal cord
at 1, 3, and 7 dpi in saline- (A) and MaR1 (B)-treated mice. C, D, Graphs showing quantification of macrophage andmicroglial cells from FACS analysis. Note the reduced numbers of macrophages
at day 7 after MaR1 treatment, demarcating the enhanced resolution plateau triggered by this SPM. However, microglial counts were not modulated by MaR1 for the first week after injury. *p
0.05 versus saline. Two-way ANOVA with Bonferroni’s post hoc test was used to analyze significant differences (n	 6 per time point and group). Data are shown as mean SEM.
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withMaR1 at 7 dpi (Mann–Whitney test, p	 0.0286), indicating
that this SPM enhanced neutrophil phagocytosis in SCI (Fig.
7A,B). Therefore, exogenous administration of MaR1 drives
macrophage activation toward a more restorative phenotype af-
ter SCI and enhances efferocytosis.
Administration of MaR1 reduces tissue damage and improves
locomotor recovery after SCI
Finally, we investigated whether MaR1 improves functional and
histological outcomes after SCI.Mice treated withMaR1 demon-
strated significant improvement in locomotor recovery, resulting
in elevated BMS scores (two-way ANOVA, Bonferroni’s post hoc
test; effect of day F(8,36)	 129.5, p 0,0001; effect of treatment
F(1,36)	 11.07, p	 0,0020). Post hoc analysis revealed significant
differences in BMS score starting at 3 dpi and remaining signifi-
Table 1. Protein levels of cytokines silenced significantly by MaR1 in SCI
Naive Saline MaR1
IL-3 ND 0.56 0.03 ND
IL-6 0.94 0.03 671 133 291 56.7*
IL-13 ND 4.19 1.38 ND
CSF3 ND 1179 182 741 118*
CXCL1 2.81 0.23 219 67.6 87.5 21.3*
CXCL2 4.59 0.30 119 17.9 41.4 7.50*
CXCL5 ND 4.80 0.86 ND
CCL3 ND 21.5 2.52 13.3 1.18*
CCL4 ND 28.9 3.47 17.7 1.46*
*p 0.05, MaR1 versus saline.
ND, Not detectable (i.e., below the limits of detection).
Figure 5. Acutemechanistic signaling underlying systemicMaR1 treatment at the lesion site.A, Cytokine protein level profile 24 h afterMaR1 treatment is characterized by a reduced expression
of chemokines (CXC12, CXCL1, CCL3, CCL4, andCSF3) and theproinflammatory cytokine IL-6 (black bars) as indicatedby Luminex analysis.B,C,Westernblot analysis showingdifferent inflammatory
intracellular pathways in contused spinal cord at 24 h after injury. Note that MaR1 treatment attenuated the activation of STAT-1, STAT-3, STAT-5, p38, and ERK1/2 signaling at the lesion site, but
does not limit NF-B and PI3K/Akt activation after SCI. *p 0.05 versus saline. One-way ANOVA with Dunnet’s post hoc test was used to analyze significant differences (n	 3 in uninjured and
contused saline-treated injured mice; n	 4 in contused MaR1-treated mice). Data are shown as mean SEM.
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cantly enhanced up the end of the follow-up (Fig. 8A). At 28 dpi,
50% of mice treated with saline showed plantar placement with
no stepping, whereas the remaining 50% performed occasional
stepping (BMS score of 3.5  0.22). However, all mice treated
with MaR1 displayed plantar placement with occasional or fre-
quent stepping (score 4.58 0.22).Mice administeredMar1 also
showed faster speeds of locomotion on the treadmill, although
this was not statistically significant (Mantel–Cox test p 	 0.07;
Fig. 8B). In addition, DigiGait analysis revealed that MaR1 im-
proved specific parameters of locomotion such as gait symmetry
Figure 6. MaR1 redirects macrophages toward a prorepair phenotype after SCI. A, Representative FACS analysis density plots of Ly6C macrophages in saline- and MaR1-treated mice at 7 dpi.
B, Graph showing proportion of different macrophage subsets in the injured spinal cord at 7 dpi. C, D, Representative FACS histograms plots of M1 and M2 markers in injured spinal cord for
macrophages (C) andmicroglial cells (D) at 7dpi.E,F, Graphs showing thequantificationofmacrophages (E) andmicroglial cells (F ) expressingM1andM2markers after SCI. *p0.05 versus saline.
Student’s t test was used to analyze significant differences between MaR1 and control mice (n	 6 per group). Data are shown as mean SEM.
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(Student’s t test, unpaired, two-tailed, t 	 3.523 df 	 7; p 	
0.0097) and stance/width stepping variability (Student’s t test,
unpaired, two-tailed, t	 2.465 df	 7; p	 0.0431; Fig. 8C) after
SCI, further demonstrating improvement in locomotor control
in mice treated with MaR1. No differences were found in other
DigiGait parameters.
We then assessed whether the improvement in locomotor
function ofMaR1-treatedmicewas associatedwith a reduction in
secondary tissue damage after SCI. Histological sections stained
with LFB revealed that MaR1 increased myelin content at the
injury epicenter and in sections located at 200 m rostral and
caudal to the injury (Fig. 8D,E). To determine whether this
greater amount of myelin was due to reduced demyelination,
reduced axonal damage, or both, we quantified the number of
axons (NF) and those that had myelin sheath (NF/MBP) in
the dorsal columns at the injury epicenter, the most damaged
area of the spinal cord. These analyses reveal thatMaR1 enhanced
both axonal sparing (Student’s t test, unpaired, two-tailed, t 	
2.479 df	 18; p	 0.0233) and reduced demyelination after SCI
(Student’s t test, unpaired, two-tailed, t 	 2.931 df 	 18; p 	
0.0089; Fig. 8F,G). In addition, we found that MaR1 improved
neuronal survival in the ventral horn in caudal regions to the
injury epicenter (two-way ANOVA, Bonferroni’s post hoc test;
effect of day F(16,306) 	 64,43, p  0,0001; effect of treatment
F(1,306)	 17,61 p 0,0001; Fig. 8H, I). Overall, these data dem-
onstrate that treatment with MaR1 reduces secondary tissue
damage and improves functional outcomes after SCI.
Discussion
Traditionally, therapeutic approaches for acute SCI have sought
to modulate the proinflammatory limb of the inflammatory re-
sponse with limited success. Here, we identify impaired resolu-
tion of inflammation as a prominent feature of the dysregulated
inflammatory response after SCI due to incomplete clearance of
immune cells from the lesion site. We show that this impaired
resolution coincides with severely blunted SPM biosynthesis, in
contrast to peripheral, self-resolving inflammatory lesions, which
are characterized by an early lipid mediator class shift (Serhan,
2014; Serhan et al., 2015). Our data reveal that systemic admin-
istration of the resolution agonist MaR1 stimulated various bio-
logical mechanisms, which resulted in improved resolution of
inflammation andmarked improvement of locomotor outcomes.
PUFAs are key regulators of the inflammatory response be-
cause they control several processes involved in the onset and
resolution of this physiological process (David et al., 2012c; Serhan,
2014; Serhan et al., 2015). Among them, n-3 PUFA ( 3-fatty acids)
has been specially brought to the attention of the scientific com-
munity due to its therapeutic effects in several inflammatory dis-
eases. In particular, the n-3 PUFAs DHA and EPA, which are
enriched in oils derived from fish and algae, are used extensively
as dietary supplements and have been found to exert beneficial
actions in a number of conditions in which inflammation con-
tributes to the course of pathology, including SCI (King et al.,
2006; Huang et al., 2007; Lo´pez-Vales et al., 2010).
More recently, EPA andDHA lipid-derivedmediators known
collectively as SPMs have been identified as key players in the
resolution of inflammation and regulators of homeostasis
(Schwab et al., 2007; Buckley et al., 2014; Serhan, 2014; Serhan et
al., 2015). The importance of SPMs in regulating inflammation is
evident in many inflammatory disorders such as atherosclerosis,
asthma, and ulcerative colitis, in which there is an absence of or
insufficient or delayed production of SPMs (Serhan, 2014; Ser-
han et al., 2015). Importantly, the exogenous administration of
SPMs reduces inflammation and prevents the detrimental effects
exerted by the immune cells due to the failure to produce SPMs in
the pathogenesis of different inflammatory diseases (Serhan,
2014; Serhan et al., 2015). Our results suggest that a similar sce-
nario also occurs after SCI because the dysregulation of the reso-
lution of inflammation coincides with the inefficient synthesis of
SPMs.
Among the different family members of SPMs, maresins have
been the least characterized. This family of SPMs derived from
macrophages consists of two members, MaR1 (Serhan et al.,
2009) and the more recently identifiedMaR2 (Deng et al., 2014).
MaR1 exerts potent actions in regulating inflammation resolu-
tion, but also in preventing nociception after inflammatory- and
chemotherapy-induced neuropathic pain and stimulating tissue
Figure 7. MaR1 increases efferocytosis after SCI. A, Representative FACS analysis histogram plots of the specific neutrophil marker Ly6G in macrophages at 7 dpi and after saline or MaR1
treatment. B, Bar plot shows the increased in Ly6G median fluorescence intensity (MFI) in macrophages when the cell membrane is permeabilized, which is indicative of neutrophil phagocytosis.
Note that MaR1 increased by2-fold the engulfment of neutrophils bymacrophages. *p 0.05 versus saline. Mann–Whitney test was used to analyze significant differences (n	 4 per group).
Data are shown as mean SEM.
11740 • J. Neurosci., November 29, 2017 • 37(48):11731–11743 Francos-Quijorna et al. •Maresin 1 in Spinal Cord Injury
regeneration in Planaria (Serhan et al., 2012; Serhan, 2014). Sim-
ilar potent anti-nociceptive actions have also been demonstrated
with other SPMs (Ji et al., 2011) and with some of the SPM
pathway markers such as 17-HDHA (Lima-Garcia et al., 2011).
Although the purpose of the present work was not to assess the
effects of MaR1 on nociception after SCI, this should be consid-
ered for future studies because neuropathic pain compromises
the quality of life in nearly 70% of SCI patients (Eaton, 2006). It
should be noted that the resolving actions of MaR1 seem to be
more potent than those exerted by other resolving agonists such
Figure 8. MaR1 improves locomotor recovery and attenuates secondary tissue damage after SCI. A, Mice treated with MaR1 show significant improvement in locomotor skills assessed by the
nine-point BMS. The BMS score of MaR1 treated mice inclined to significantly elevated levels starting at 3 dpi and remained consistent up the end of the follow-up (28 dpi) compared with
saline-treated controls. B, Mice administered MaR1 also showed faster speeds of locomotion on the treadmill. C, DigiGait analysis revealed that MaR1 improved specific parameters of locomotion
such as gait symmetry and stance/width stepping variability after SCI, further validating consolidated locomotor control in mice treated with MaR1. D, Quantification of myelin content at various
distances rostral and caudal to the injury epicenter.E, Representativemicrographs showingmyelin areaat the injury epicenter in section stainedwith LFB fromsaline-treated (left) andMaR1-treated
(right) mice. F, Quantification of axons (NF) and myelinated axons (NF/MBP) in the dorsal column at the injury epicenter from saline-treated (left) and MaR1-treated (right) mice.
G, Representative micrographs showing dorsal neurofilament (red) and MBP (green) staining at the injury epicenter from saline-treated (left) and MaR1-treated (right) mice. H, Quantification of
ventral horn neuron survival at various distances rostral and caudal to the injury epicenter revealing improved neuronal survival caudal to the lesion in the MaR1-treated group. I, Representative
micrographs showing sparing of ventral horn neurons in saline-treated (left) andMaR1-treated (right) mice in tissue sections stained against NeuN at 400m caudal to the injury epicenter. *p
0.05; two-way repeated-measures ANOVA, Bonferroni’s post hoc test in A, D, and H; t test in C and F; Mantel–Cox test in B (n	 10 per group). Data are shown as mean SEM.
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as RvD1 because it was shown to stimulate greater efferocytosis
by human macrophages at a 1 nM concentration (Serhan et al.,
2012).
Here, we report that daily systemic treatment with very low
doses of 7S-MaR1 (1 g/mouse) after SCI accelerates and en-
hances neutrophil clearance and reduces macrophage accu-
mulation in the lesioned spinal cord, two critical steps for the
resolution of inflammation. 7S-MaR1 is an analog ofMaR1 and is
currently not known to been an isomer produced during biosyn-
thesis. The present work shows that 7S-MarR1 shares the protec-
tive actions of MaR1 and can be useful for further studies on
mechanisms of action of MaR1. Because this is, to the best of our
knowledge, the first report assessing the effects of MaR1 in the
CNS, we investigated the mechanisms underlying the resolving
effects of MaR1 in SCI.
Recruitment of leukocytes into the lesioned spinal cord is reg-
ulated by proinflammatorymediators such as cytokines (David et
al., 2012a; Popovich, 2014). MaR1 also downregulated the ex-
pression of cytokines in vitro in mouse models of both colitis and
acute respiratory distress syndrome (Serhan et al., 2009; Marcon
et al., 2013; Abdulnour et al., 2014). Our results in SCI indicate
that MaR1 leads to reduced protein levels of several prominent
proinflammatory cytokines in the spinal cord at 24 h after injury,
including IL-6, CSF3, and different members of the chemokine
family. Note also that MaR1 did not attenuate the expression of
the anti-inflammatory cytokine IL10, suggesting a preferential
action of this SPM in reducing proinflammatory cytokines.
Cytokines mediate inflammation by acting on specific recep-
tors that activate different intracellular inflammatory cascades.
Little is known about the intracellular cascades modulated by
MaR1; however, a previous report showed that this resolving
agent limitedNF-B activation (Marcon et al., 2013). Our results
reveal that MaR1 did not abrogate this transcription factor after
SCI. Similarly, PI3K/Akt signaling pathway was not affected by
this SPM.MaR1 turned off several MAPK and JAK/STAT signal-
ing pathways that are known to exert important proinflamma-
tory actions in SCI without affecting the activation of STAT6,
which is required for the suppressive effects of anti-inflammatory
cytokines (David et al., 2012b). Both the cytokine and inflamma-
tory signaling changes after MaR1 at 24 h after injury is likely to
limit the subsequent infiltration of neutrophils andmacrophages
in the lesion site and, consequently, accelerate the reduction in
their numbers after SCI.
Cytokines and signaling pathways also regulate the phenotype
of macrophages. These cells can differentiate into two major
types in vitro: (1) M1 macrophages, which display a proinflam-
matory profile and may mediate cytotoxic actions; and (2) M2
macrophages, which have anti-inflammatory effects and pro-
mote tissue healing and repair (Murray et al., 2014; David et al.,
2015). However, microglia and macrophages in SCI cannot be
defined within the simple M1–M2 dichotomy described in cell
culture conditions, but rather form a broad spectrum of activa-
tion states (David et al., 2015; Francos-Quijorna et al., 2016).
MaR1 was reported previously to shift the macrophage pheno-
type toward M2 in cell culture (Dalli et al., 2013). Here, we ob-
served that, after SCI, MaR1 did not induce the expression of the
classical M2 markers significantly in macrophages; however, it
led to a significant reduction in the expression of M1 markers
such as iNOS and Ly6C inmacrophages, but notmicroglia. These
results therefore suggest thatMaR1 skewsmacrophage activation
toward a phenotype more conducive for tissue repair in the le-
sioned CNS in vivo. Interestingly, this is not the only effect that
MaR1 exerted on this leukocyte subset. We also found that the
administration of this SPM stimulated macrophages to increase
neutrophil phagocytosis in the lesioned spinal cord. Earlier stud-
ies have shown that MaR1 induced uptake of apoptotic neutro-
phils and A42 in macrophages and microglia, respectively, in
culture (Serhan et al., 2012; Zhu et al., 2016). However, this is the
first study revealing that, similar to RvD and RvE, MaR1 pro-
motes neutrophil phagocytosis by macrophages in vivo (Schwab
et al., 2007; Serhan, 2014). Therefore, the accelerated and in-
creased clearance of neutrophils observed after SCI by MaR1
treatment could be explained by both the effects of this immu-
noresolvent agent on the phagocytic activity of macrophages to
clear neutrophils (efferocytosis) and by its suppressive actions on
cytokine levels and inflammatory signaling pathway activation.
Recent studies demonstrated that MaR1 regulates T cells and
platelets (Chiurchiu` et al., 2016; Lannan et al., 2017), sowe donot
discard the idea that the beneficial actions of MaR1 in SCI could
be also due to the effects of this SPMs on other cell types.
In conclusion,weprovide clear evidence thatMaR1 is effective at
enhancing multiple stages of the resolution of inflammation after
SCI. These include: downregulation of cytokines, silencing of in-
flammatory pathways, reduction of neutrophil and macrophage
counts, shift in macrophage phenotype, and stimulation of the
phagocytic activity of macrophages. Importantly, all of the bio-
logical effects induced by MaR1 treatment led to significant
improvement in locomotor function and protection against sec-
ondary tissue damage. The present results support the concept
that the inappropriate biosynthesis of SPMs after SCI hampers
resolution of inflammation and contributes to the physiopathol-
ogy of SCI. Because aberrant production of SPMs is also reported
in the CSF of patients with Alzheimer’s disease andmultiple scle-
rosis (Pru¨ss et al., 2013; Zhu et al., 2016), the administration of
immunoresolvents may constitute an effective therapeutic ave-
nue for the treatment of acute SCI and other neurological condi-
tions in which inflammation contributes to the course of the
disease and impaired function.
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